GlassScriptPhysician profile
Karen Baker Mesa
NPI 1023165875
$2,758.37
in general payments reported to CMS, 2019-2025
22 companies · $735 in 2025
The $735 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $579 · 2022: $256 · 2023: $550 · 2024: $639 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,758 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,758.23 |
| Education | $164.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $393.85 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $391.22 | 2023-2025 | Sotyktu |
| Amgen INC. | $349.50 | 2022-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $227.33 | 2021-2025 | Aklief |
| Arcutis Biotherapeutics, INC. | $210.99 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $196.09 | 2021-2025 | Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $174.76 | 2021 | |
| Pfizer INC. | $143.58 | 2021-2023 | |
| Sun Pharmaceutical Industries INC. | $102.04 | 2021-2025 | Absorica Ld, Winlevi |
| Journey Medical Corporation | $92.92 | 2023-2025 | |
| Genzyme Corporation | $63.84 | 2021-2022 | |
| Revance Therapeutics, INC. | $52.57 | 2024 | Daxxify |
| Cipher Pharmaceuticals US LLC | $51.03 | 2025 | Natroba, Spinosad |
| Vyne Pharmaceuticals INC. | $50.52 | 2021 | |
| Ucb, INC. | $50.15 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $46.32 | 2023-2025 | Seysara |
| Regeneron Healthcare Solutions, INC. | $44.74 | 2022 | |
| Organon LLC | $33.54 | 2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $31.30 | 2025 | |
| Mayne Pharma Commercial LLC | $22.49 | 2023-2025 | |
| Lilly USA, LLC | $15.81 | 2024 | Olumiant |
| Botanix Sb INC | $13.78 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Baker Mesa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.